Asset Details
Do you wish to reserve the book?
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Do you wish to request the book?
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
2007
Overview
Sunitinib is one of several new antiangiogenic agents undergoing tests of efficacy in the treatment of various types of cancer. Renal-cell carcinoma of the clear-cell type is particularly important in this regard because of the evidence that mutations in the
VHL
gene result in stimulation of cellular receptors that promote angiogenesis and tumor growth. This trial found promising results with sunitinib in the treatment of metastatic renal-cell cancer.
Sunitinib is one of several new antiangiogenic agents undergoing tests of efficacy in the treatment of various types of cancer. This trial found promising results with sunitinib in the treatment of metastatic renal-cell cancer.
Renal-cell carcinoma is the most common cancer of the kidney.
1
Up to 30% of patients with renal-cell carcinoma present with metastatic disease,
2
,
3
and recurrence develops in approximately 40% of patients treated for a localized tumor.
2
,
4
Since renal-cell carcinoma is highly resistant to chemotherapy, interleukin-2 or interferon alfa is widely used as first-line treatment of metastatic disease. Response rates with these cytokines are low (5 to 20%), and median overall survival is approximately 12 months.
5
–
9
Alternative treatments have been lacking for renal-cell carcinoma that is resistant to cytokines. In two recent uncontrolled trials, sunitinib malate, an antiangiogenic agent, . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Angiogenesis Inhibitors - adverse effects
/ Angiogenesis Inhibitors - therapeutic use
/ Biological and medical sciences
/ Carcinoma, Renal Cell - drug therapy
/ Carcinoma, Renal Cell - mortality
/ Carcinoma, Renal Cell - secondary
/ Female
/ Humans
/ Interferon-alpha - adverse effects
/ Interferon-alpha - therapeutic use
/ Kidney Neoplasms - drug therapy
/ Kidney Neoplasms - mortality
/ Kidney Neoplasms - pathology
/ Kidneys
/ Male
/ Nephrology. Urinary tract diseases
/ Protein Kinase Inhibitors - adverse effects
/ Protein Kinase Inhibitors - therapeutic use
/ Receptors, Platelet-Derived Growth Factor - antagonists & inhibitors
/ Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors
